The recent detection of vaccine-derived poliovirus (VDPV) in London (UK) and a case of
paralytic polio in New York (USA) have highlighted how the scourge of poliomyelitis has not …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …

Although there have been no cases of serotype 2 wild poliovirus for more than 20 years,
transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic …

Thirty-one ongoing and new cVDPV type 2 (cVDPV2) outbreaks were documented during
July 2019–February 2020; nine outbreaks spread internationally. New cVDPV2 outbreaks …

RNA viruses generate defective viral genomes (DVGs) that can interfere with replication of
the parental wild-type virus. To examine their therapeutic potential, we created a DVG by …

Background Continued emergence and spread of circulating vaccine-derived type 2
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …

Enormous progress has been made in global efforts to eradicate poliovirus, using live-
attenuated Sabin oral poliovirus vaccine (OPV). However, as the incidence of disease due to …

Although WPV1 incidence declined annually during 2015–2017, cases in Afghanistan and
Pakistan have increased since 2018. The number and geographic spread of cVDPV type 2 …

To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2),
Global Polio Eradication Initiative (GPEI) partners are working closely with countries to …